The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma.
 
Shiraj Sen
Consulting or Advisory Role - Daiichi Sankyo (Inst)
Research Funding - BioAtla (Inst); Exelixis (Inst); Jacobio (Inst); Loxo (Inst)
 
Meredith Ann McKean
Consulting or Advisory Role - Array BioPharma (Inst)
Research Funding - Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Jacobio (Inst); Moderna Therapeutics (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Tizona Therapeutics, Inc. (Inst)
 
Laura Sierra
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Jessica Ainscough
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Jay Yang
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Anthony Hamlett
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Tom Zimmerman
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Melinda Merchant
No Relationships to Disclose
 
Sant P. Chawla
Honoraria - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma